ANI Pharmaceuticals, Inc. (ANIP) announced on Monday that it anticipates its total net revenues and adjusted earnings per share to meet or exceed the expectations outlined in its fiscal year 2024 financial guidance.
In the fourth quarter, net revenues from Purified Cortrophin Gel are projected to range between $59.2 million and $59.8 million. Additionally, revenues from the combined sales of Iluvien and Yutiq are expected to fall between $26.6 million and $27.2 million.
Looking forward, the biopharmaceutical company forecasts total net revenues to be between $739 million and $759 million, with an adjusted EBITDA ranging from $182 million to $192 million for fiscal year 2025. Analysts surveyed by Thomson Reuters anticipate full-year revenues to be approximately $720.3 million.
Pre-market trading on Nasdaq has seen ANI Pharmaceuticals' stock at $54.74, reflecting a 0.55 percent decrease.
